Albumin Market Report 2026

Albumin Market Overview

• Albumin market size has reached to $7.16 billion in 2025 • Expected to grow to $10.62 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: The Rising Incidence Of Diabetes Is Driving The Market Due To Increasing Renal Complications Requiring Albumin Monitoring • Market Trend: Innovations In Animal- and Human-Origin-Free Recombinant Albumin • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Albumin Market?

Albumin is a type of protein found in blood plasma, serum, muscle, the whites of eggs, milk, and other animal substances, as well as in many plant tissues and fluids. It is a simple, heat-coagulable, and water-soluble protein that plays a crucial role in maintaining fluid balance and transporting hormones, vitamins, and enzymes throughout the body. The main types of albumin are human serum albumin, bovine serum albumin, and recombinant serum albumin. Human serum albumin is a protein found in blood plasma that helps maintain osmotic pressure and transports various substances, including hormones and fatty acids. Applications include therapeutics, drug formulation, and vaccines, components of media, and others distributed through sales channels such as business-to-customer (B2C), and business-to-business (B2B). The end users include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.

What Is The Albumin Market Growth Forecast?

The albumin market size is expected to see strong growth in the next few years. It will grow to $10.62 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to advancement in recombinant albumin technology, growing demand for personalized medicine, expansion of albumin in drug delivery systems, increasing biopharmaceutical manufacturing, rising investment in therapeutic and cosmetic applications. Major trends in the forecast period include rising demand for human serum albumin in therapeutics, growing use of albumin in drug formulations and vaccines, expansion of recombinant albumin applications in biopharma, increasing adoption of albumin in cell culture and diagnostic kits, focus on albumin-based research and personalized medicine.

Global Albumin Market Segmentation

1) By Type: Human Serum Albumin, Bovine Serum Albumin, Recombinant Albumin 2) By Application: Therapeutics, Drug Formulation And Vaccines, Component Of Media, Other Applications 3) By End-User: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Research Institutes Subsegments: 1) By Human Serum Albumin: Plasma-Derived Human Serum Albumin, Recombinant Human Serum Albumin, Human Serum Albumin For Therapeutic Use (In Liver Disease, Burns), Human Serum Albumin For Drug Delivery And Research Applications 2) By Bovine Serum Albumin: Bovine Serum Albumin For Laboratory Use (In Cell Culture), Bovine Serum Albumin For Diagnostic Kits, Bovine Serum Albumin As A Stabilizer In Vaccines And Biopharmaceuticals 3) By Recombinant Albumin: Recombinant Human Albumin For Therapeutic Applications, Recombinant Albumin For Biopharmaceutical Formulation, Recombinant Albumin For Cosmetic And Personal Care Applications, Recombinant Albumin For Research And Diagnostic Applications

What Is The Driver Of The Albumin Market?

The rising incidence of diabetes is expected to propel the growth of the albumin market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, which over time can cause renal complications such as diabetic nephropathy. A key factor behind the rising incidence of diabetes is increasing obesity rates, demonstrated by extensive epidemiological evidence showing a strong correlation between higher body mass index levels and substantially elevated diabetes risk. Albumin supports patient management by helping monitor kidney function and guide treatment interventions in diabetic individuals. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, diabetes affected an estimated 589 million adults and 9.5 million people with type 1 diabetes in 2024 including 1.9 million children and adolescents and the total number of individuals living with the disease is projected to rise to 853 million by 2050. Therefore, the rising incidence of diabetes is driving the growth of the albumin industry.

Key Players In The Global Albumin Market

Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.

Global Albumin Market Trends and Insights

Major companies operating in the albumin market are developing innovative products, such as an animal- and human-origin-free recombinant albumin, to better serve customers with advanced features. An animal- and human-origin-free recombinant albumin refers to a type of albumin that is manufactured using a non-mammalian expression system, such as yeast, and does not contain any components derived from animals or humans. For instance, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), and Heartseed Inc., a Japan-based clinical-stage biotech company, partnered to launch Recombin, a critical excipient that will be used in the production of Heartseed's investigational cell therapy, HS-001, as its first-in-human clinical trial commences. This collaboration marks a significant milestone in the development of HS-001, which is poised to revolutionize the treatment of various diseases. The inclusion of recombination in the manufacturing process ensures the optimal performance and stability of the cell therapy, further solidifying its potential for therapeutic success.

What Are Latest Mergers And Acquisitions In The Albumin Market?

In November 2025, Evonik Industries AG, a Germany-based specialty chemicals company, partnered with InVitria to expand global access to animal-component-free recombinant human serum albumin (rHSA) for biopharmaceutical and advanced therapy applications. Through this partnership, Evonik aims to strengthen its portfolio in biologics, cell therapies, and formulation technologies by integrating InVitria’s high-purity recombinant albumin into its solutions. InVitria is a US-based biotechnology company that produces animal-free recombinant proteins, including recombinant albumin used in vaccines, cell culture, and therapeutic development.

Regional Outlook

North America was the largest region in the albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Albumin Market?

The albumin market consists of sales of egg albumin, plant-based albumin, and recombinant human albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albumin Market Report 2026?

The albumin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albumin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.